Headache Characteristics In COVID-19 Pandemic-A Survey Study

Headache Characteristics In COVID-19 Pandemic-A Survey Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research article Headache Characteristics In COVID-19 Pandemic-A Survey Study Özge Uygun, Mustafa Ertas, Esme Ekizoğlu, Hayrunnisa Bolay, Aynur Özge, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-59636/v2 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 13 Oct, 2020 Read the published version in The Journal of Headache and Pain → Version 2 posted 4 You are reading this latest preprint version Show more versions Abstract Background Headache is the most common COVID-19-related neurological symptom. We aimed to reveal diagnostic clues of headache for COVID-19 infection and to investigate the course of primary headaches during the pandemic. Methods We developed a detailed web-based questionnaire screening the characteristics and course of headaches besides clinical COVID-19 features. The participants were grouped according to being diagnosed with COVID-19 infection or not, and having previous or new-onset headaches. The COVID-19 related headache features and their associations with other clinical features were investigated. A binary logistic regression model was performed to differentiate the characteristics of headache related to COVID-19. Findings A total of 3458 participants (2341 females;67.7%, 1495 healthcare workers;43.2%) with a mean age of 43.21±11.2 years contributed to the survey. Among them, 262 participants had COVID-19 diagnosis and 126 (48.1%) were male. The rate of males in the group without COVID-19 was 31% (991 out of 3196 participants) showing significant gender difference between groups (p<0.000). COVID-19 related headaches were more closely associated with anosmia/ageusia and gastrointestinal complaints (p<0.000 and p<0.000), and showed different characteristics like pulsating, pressing, and even stabbing quality. Logistic regression analyses showed that bilateral headache, duration over 72 hours, analgesic resistance and having male gender were significant variables to differentiate COVID-19 positive patients from those without COVID-19 (p=0.04 for long duration and p<0.000 for others). A worsening of previous primary headaches due to the pandemic-related problems was not reported in the majority of patients. Interpretation Bilateral, long-lasting headaches, resistance to analgesics and having male gender were more frequent in people with COVID-19 in conjunction with anosmia/ageusia and gastrointestinal complaints. These features may be helpful for diagnosing the headache related to COVID-19 during the pandemic. Infectious Diseases COVID-19 infection headache migraine Figures Figure 1 Figure 2 Figure 3 Figure 4 Introduction Coronavirus disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) first emerged in Wuhan towards the end of 2019. 1 The pandemic is now influencing the whole world with a large number of deaths, besides many other medical and social consequences. The most common clinical picture of COVID-19 is characterized by manifestations of the respiratory system, as the name of the virus implies. However, many other complaints such as anosmia, ageusia, diarrhea and also headache have been noted in the clinical spectrum, with an increasing number of patients. 2 A handful of reports disclosed that headache is among the COVID-19-related symptoms, showing highly variable rates across the studies. 3-6 There are some studies and reviews highlighting that the most common neurological symptom is headache, often accompanied by high fever, moreover headache can occasionally be seen alone as the first sign of the disease. 2, 7 A recent meta-analysis reported that the prevalence of headache was 10.9% with a high level of heterogeneity. 8 Therefore, detailed questioning of the presence of headaches in patients who are admitted to the emergency and outpatient departments is still an important step in the prompt recognition of the infection in some patients. In clinical observations and small case series, COVID-19 related headache was described as acute at onset, usually occurring in a different character unlike previous headaches. 9, 10 However, there are no systematic data on the headache characteristics. Another important problem is the situation of patients with previous severe headaches like migraine in the COVID-19 pandemic era. COVID-19 itself or its psycho-sociological effects may cause more headache burden, along with the problems of quarantine and these points are not yet investigated thoroughly. In this study, we aimed to reveal COVID-19 related headache characteristics and its associations. Our secondary aims were to investigate the features and course of pre-existing headaches as well as new-onset ones in participants without COVID-19 but having headaches during the pandemic. Methods Design of a web-based questionnaire After the emergence of COVID-19 for the first time in March 2020 in our country, the complaints of peculiar headaches in consulted cases and some distinctive headache features in admitted patients attracted our attention. For this reason, a detailed questionnaire was developed focusing on headache characteristics, besides some clinical COVID-19 features by a panel of headache experts, after rounds of online discussions. The number of the questions was tried to be kept in an acceptable limit to optimize the attention during answering the survey and the survey was tested before its submission by five patients for clarity of the questions. The web-based, user-friendly technical design was planned by the experts of the Istanbul University Department of Informatics. The features of previous headaches were screened and headache diagnosis was made according to International Classification of Headache Disorders, 3 rd version (ICHD-3 criteria). 11 Possible changes in the headache course during the pandemic along with perceived precipitating factors and related characteristics were queried with scrutiny. Important characteristics such as the duration, frequency, course, localization, the severity of headaches, and treatment response were asked separately before and during the COVID-19 pandemic. The questionnaire has also asked if the participant had been diagnosed with COVID-19 as well as the symptoms of COVID-19 infection in detail for relevant patients. Even if the patient was not diagnosed with COVID-19, factors secondary to the pandemic lifestyle as possible triggers of headache, such as wearing a mask, having the fear of infection, etc. were evaluated. The questionnaire has included a total of 39 questions, and based on four different parts, in terms of demographics, previous headache features, reported COVID-19 infection features, and details of the headache course after the pandemic. The participants were invited by means of social media (using Twitter, Instagram or Whatsapp) using a web-based link, suitable also for smart phones, after the Ethics Committee approval (17.04.2020/520). Discharged COVID-19 patients of the Istanbul University Faculty of Medicine Hospital were invited by text messages to volunteer the survey, in order to increase the number of patients with COVID-19 infection-related headache. Inclusion and exclusion criteria Eligible participants older than 18 - years who had a COVID-19 infection experiencing headache among their symptoms or who had any type of headache before the pandemic, or developed new-onset headaches were included. The volunteers who participated in the survey were grouped according to being diagnosed with COVID-19 infection or not. In our country’s protocol, only those patients who have polymerase chain reaction (PCR) positivity, are diagnosed with COVID-19. Especially, healthcare workers were encouraged to attend the study. Figure 1 shows the flowchart of our study. Surveys completed by participants under age of 18 or those reporting inconsistent responses were excluded. Participants without headache during the pandemic were not included in the statistical analysis. Study period The duration of survey implementation was planned as 15 days, starting on 1 May 2020. Although reaching a high number in a few hours, the survey was continued to the end of this period to include more patients with COVID-19 related headaches. Statistical analysis Descriptive analyses were applied for four main groups of participants (Figure 1, Table 1); the participants with or without COVID-19 were compared in relation to the presence or absence of previous headaches before the pandemic of COVID-19 in regard to headache characteristics by the chi-square test and t-test where appropriate. A binary logistic regression model was performed to explore the differentiating headache variables between COVID-19 positive and negative cases. The odds ratios were calculated for significant infection-related features, such as anosmia/ageusia and gastrointestinal complaints like diarrhea. IBM SPSS Statistics Version 22 was used and p<0.05 was considered as statistically significant. Results A total of 3458 participants (2341 females) contributed to our survey. Of this main group with and without headache during the pandemic, 262 patients were diagnosed with COVID-19 by PCR (Figure 1). These 262 patients were grouped as COVID-19 positive including 136 females (51.9%) and 89 healthcare workers (9.8%). The characteristics of patients with COVID-19 infection In the COVID-19 positive group, the rate of males was 48.1% (126 out of 262 patients), whereas in the COVID-19 negative group this rate was 31% (991 out of 3196 participants), showing a significant gender difference (p<0.000). Headaches lasting over 72 hours were reported by 10.3% (27 out of 262 participants) of COVID-19 infected patients versus 4.1% (130 out of 3196 participants) of the COVID-19 negative group (p<0.000). In this study, 1968 participants with or without COVID-19 infection reported headache attacks during the pandemic. Among them 714 (36.3%) had migraine and 1077 (54.7%) participants were diagnosed with tension type headache (TTH) according to ICHD-3 criteria. The headache characteristics, accompanying features, treatment responses of these patients experiencing headache during the pandemic, according to having or not having prior headaches were shown in Table 1, comparatively. Osmophobia was more frequently reported in the group with COVID-19. Most of the COVID-19 cases (71%) experienced nausea and gastrointestinal symptoms, for example, diarrhea/stomachache were present in more than half of them. Interestingly, pulsating quality was more pronounced in patients with previous headaches in the group with COVID-19 in comparison to the group with history of new onset headache. The great majority of COVID-19 patients with previous headaches (79.5%, 89 out of 112 responders) reported that their new emerging headaches during the infection period were different from their usual headaches; among them, 50% (56 participants) disclosed that this new headache was totally different, whereas 29.5% (33 participants) reported some differences despite some similar properties resembling previous headache features. On the other hand, among the participants without COVID-19 diagnosis but with previous headaches, 62.7% (785 out of 1252 responders) disclosed that their headaches were identical to the pre-existing episodes. Among them, only 13.9% (174 participants) reported entirely different attacks, whereas 23.4% (293 participants) reported partly different headaches. Severity of the previous headaches did not relate to receiving COVID-19 diagnosis; COVID-19 positive patients had reported headaches of mild intensity in 26.6% (34 out of 128 responders), moderate-intensity in 47.7% (61 participants), severe in 23.4% and very severe (dependent to bed/hospital) in 2.3% (3 participants). The corresponding rates of headache intensity were 27.7% (484 out of 1747 responders), 46.7% (816 participants), 21% (367 participants), and 4.6% (80 participants) in COVID-19 negative participants. Among all 262 patients diagnosed with COVID-19, 40% (104 participants) reported high fever (over 38˚C), 49.2% (128 participants) prominent cough, 48.3% (125 participants) sore throat and 33.5% (87 participants) shortness of breath. On the other hand, diarrhea/stomachache was present in 57.7% (150 participants) and lastly anosmia/ageusia was present in 60.4% (157 participants) of this group. There were 59 (22.5%) COVID-19 positive patients who had previous headaches, who did not experience headaches during the pandemic period of 2 months at the time of their participation in the survey. At least one close contact with the disease was present in 65.4% (170 participants) of the COVID-19 positive patients and 90.1% of the patients lived under quarantine. Triggers of headache in the study population The triggers of headache reported by the participants are shown comparatively in COVID-19 positive and negative cases in the Figure 2; the second part of this figure shows the triggers reported by healthcare workers compared to the others. We noticed that stress was the most common trigger up to 30% of the participants as seen as in the Figure 2 and social isolation triggered headache noteworthy in patients without COVID-19. On the other hand, the patients diagnosed with COVID-19 reported also infection itself and the drugs as triggers of headache. The course of headache in participants during the pandemic The reported changes in the headache course after the pandemic were shown in Figure 3. Among the responding 1886 patients, 23.3% reported an increase in severity of headache, 28.7% reported an increase of the headache duration, and lastly 14% reported deterioration in the accompanying symptoms. The decreased headache frequency in 12.3% of the group was remarkable. Our analysis showed that among the patients with pre-existing migraine diagnosis, the frequency of pulsating headache character decreased from 60.5% (328 out of 542 pts) to 55% (22 out of 40 pts) in those receiving COVID-19 diagnosis. However, this latter rate was still significantly higher in comparison to 34.1% (31 out of 91 pts) compared to COVID-19 positive patients without previous headache (p=0.033). The worsening of previous headache and analgesic unresponsiveness did not show any difference in relation to ages of the participants with COVID-19. Differentiating variables of COVID-19 related headache The important differentiating variables for COVID-19 infection patients suffering from headaches were summarized in Table 2 and graphed as Figure 4, with calculated Odds ratios (OR). According to our findings, the presence of bilateral headache, duration over 72 hours, male gender, analgesic resistance, gastrointestinal symptoms and anosmia/ageusia showed increased risk of having headache related to COVID-19 infection. Additionally, binary logistic regression was computed with significant headache variables which could be observed in everyday practice to distinguish COVID-19 related headaches. The model summary showed a -2 Log likelihood ratio of 1003.6 (Nagelkerke R Square: 0.105) and using this model 88.6% of the COVID-19 patients could be classified correctly with a cut off value of 0.5. We did not enter infection-related features in this analysis, because they are clear clues for COVID-19 and do not appear in control cases. Our findings disclosed that bilateral headache, duration over 72 hours, male gender, and analgesic resistance were important variables to differentiate between COVID-19 positive patients from negative ones, showing statistical levels as p=0.04 for long duration of headaches and p<0.000 for the remaining variables (Supplementary Table 1). Discussion This first careful analysis of emerging headache characteristics in the pandemic showed that COVID-19 related headaches are more closely associated with anosmia/ageusia and gastrointestinal complaints, in comparison to other usual infection findings. Moreover, bilateral headache, duration over 72 hours, male gender, and analgesic resistance are highly important variables to differentiate between COVID-19 positive patients from negative ones. Although we expected prominent worsening of primary headaches due to the pandemic-related problems, this happened only for less than 1/3 of participants, mostly related to stress. Gender difference of COVID-19 related headaches Despite the well-known predominance of headaches in females and the fact that more than 2/3 of participants answering our survey consisted of females, COVID-19 related headaches were reported by male patients at a high rate. This interesting finding is somewhat in line with the predominance of COVID-19 in male gender, with changing reported rates around 56-73%. 12-14 It could be hypothesized that this reversed gender dominance may relate to comorbidities like atherosclerosis and hypertension which are more frequent in males. However, females with nearly three times higher rates of migraine could still have outnumbered in COVID-19 related headaches. 12,15 Therefore, this finding is a striking point that needs further careful elaboration. Given the higher risk of male gender in COVID-19 cases, a protective role of female hormones or of the location of Angiotensin-converting enzyme 2 (ACE-2) on the X chromosome could be speculated. 9,12 Moreover, ACE-2 expression level which is critical for the SARS- CoV-2 entry to the cells was found different between genders. 14 There is some evidence that immune activity is more efficient in females in other viral infections. 16 It is tempting to speculate that SARS-CoV-2 may trigger some silenced genes related to innate immunity in the X chromosome, so two X chromosomes may serve for a more effective and balanced war against COVID-19 related hyperactivation of immune pathways. Moreover, estrogens and progesterone have anti-inflammatory actions partially through inflammasome activation in some models. 17 ACE also affects the display of major histocompatibility complex (MHC) class I and MHC class II peptides. 18 Thus, further work with these gender-related differences may give us some clues to find out novel protective ways against COVID-19. Possible mechanisms underlying COVID-19 related headaches in the light of our findings The underlying mechanisms of headache related to COVID-19 are not clear at this early moment. 9 A direct invasion of trigeminal nerve endings in the nasal or oral cavity by the virus seems one of the most reasonable mechanisms underlying headache according to our results showing the close relation between headache and anosmia/ageusia. Some coronaviruses were shown to be neurotropic and former SARS‐CoV has been observed in the human brain. 19,20 Therefore, it is highly likely that SARS‐CoV‐2 may also enter the nervous system via the cranial nerves. Since the first observations in China, there are many worldwide reports showing heterogeneous prevalence figures around 5-85% of loss of smell. 21, 22 These profound differences may relate to the viral load differences and a different individual immune response between younger milder symptomatic outpatients, who are eager to report their symptoms, and contrarily severe COVID-19 inpatients with prominent respiratory problems who probably under-report this relatively milder problem. It is well-known that methodological differences exist between questionnaire studies and objective measurements, the former being mostly with lower prevalence. Despite this fact, the rate of anosmia/ageusia was high in our study. These two distinct problems caused by different nerves were not easy to differentiate from each other in daily life, therefore anosmia and ageusia were evaluated together in our study. It was remarkable that nasal obstruction and rhinorrhea were frequently reported but not strictly correlated with anosmia and ageusia according to our results. Although the trans‐synaptic transfer of SARS-COV-2 is not proven yet, this possibility of the trans‐synaptic route was documented for other coronaviruses. 23 Entrance from the nasal cavity to the olfactory bulb, then spreading to the brainstem via the piriform cortex with both passive diffusion and axonal transport has been demonstrated. 24 Besides the described headache characteristics and COVID-19 related respiratory tract symptoms, abdominal pain and diarrhea should be taken into account to evaluate these patients. 3-5,25 Our study found a high rate of gastrointestinal symptoms like diarrhea/stomachache in more than half of the COVID-19 cases and also high rates of nausea (71%) as an accompanying symptom of headache. A previous interesting report from China on non-classical symptoms indicated that 21.6% of patients had gastrointestinal symptoms, associated with headache, which is a higher number in comparison to patients without gastrointestinal symptoms. 26 The intriguing relationship of headache with gastrointestinal symptoms also brings to mind several interesting mechanisms including increased circulating Calcium gene related peptide (CGRP) levels and “gut-brain axis” concept where several inflammatory mediators like Interleukin-1β (IL-1 β), Interleukin-6 (IL-6), Interleukin-8 (IL-8), and Tumor necrosis factor-α (TNF-α), besides gut microbiota, and neuropeptides including CGRP are thought to play a role in this interaction. Another relevant consideration is systemic CGRP increase, possibly induced by both angiotensin II and IL-6 levels, as CGRP is clearly associated with trigemino vascular activation resulting in headache, increased gastrointestinal (GI) motility leading to diarrhea, further triggering inflammation and vascular edema. 9,27 Taken together with the unusually high rate of ageusia-anosmia (60.4%), this data may lead us to the footsteps of the viral pathway in the brain. Thus, we may also suggest that neuronal invasion of this new coronavirus may cause the dysfunction of the network at brainstem sites, in addition to headache. Nausea and vomiting are associated GI symptoms of migraine headache, yet the diarrhea is a distinct GI feature associated with headache in COVID-19, which clearly shows that opposite influencers play role in SARS-CoV-2 infected gut and trigeminal nerve. Headache in relation with a systemic viral infection, (without signs of meningo-encephalitis) is described in the International Classification of Headache Disorders-3. The underlying mechanisms of this entity are not illuminated so far. Regarding its characteristics, diffuse pain of moderate/severe intensity, commonly with fever was noted. 11 However, in our analyses, the association of headache with fever seems not to be decisive (in all COVID-19 patients with headache, only 40% reported high fever). Also, rhinosinusitis and other respiratory tract symptoms did not seem to explain the headaches in many of these cases, as seen in Table 1. Therefore, for this emerging COVID-19 related headache, the simplistic view of a "causal" relationship with fever or upper respiratory symptoms is not explanatory. The course of headaches during the pandemic and reported triggers for headache Most of the patients with pre-existing headaches easily noticed that this was a different problem if they had COVID-19 related headache according to our survey. In a recent case report, the authors highlighted the need to consider secondary headaches, related to central nervous system infections in the setting of COVID-19 in patients experiencing refractory headache, even if the patient had chronic migraine. 28 On the other hand, it was also intriguing that 22.5% of the COVID-19 positive cases with previous headaches did not suffer from headache during the pandemic and during the infection. There is no clear explanation for the lack of headache in these cases; causes related to viral load, transmission route, or individual differences may play a role. Other interesting data were the stabile course (53%) or even decrease of the attack frequencies (12%) and reduced severity of the pre-existing headaches in the pandemic period despite the apparent stressful conditions. Social isolation may have helped to avoid stressful social interactions; a healthy diet, and mild sports activities are possible with spending more time at home, also reducing the stress of daily-work life during the pandemic; all these points were possible reasons for the better headache outcome than expected. The triggers for headaches showed significant differences between participants with and without COVID-19 infection. Headache was triggered more frequently by stress and social isolation in patients without COVID-19 whereas patients diagnosed with COVID-19 reported also infection itself and the drugs as triggers of headache. Furthermore, wearing masks as well as stress both were the main triggers of headache and were more frequently reported by healthcare workers than by the others. Standard hygiene precautions seemed to reduce the risk for the healthcare workers who did not show an increased risk for COVID-19 compared to other participants in our study. It was reported from Germany that an overall seroprevalence of SARS-CoV-2 in a tertiary hospital was low, given the standard hygiene measures taken. 29 Other differentiating features and associations of COVID-19 related headache The clinical features of COVID-19 infection in non-hospitalized adults were reported to be different from hospitalized patients warranting greater awareness of this wider spectrum of clinical symptoms. 30 Headache as the leader of the COVID-19 related neurological symptoms is the most frequent complaint in outpatient clinics. 31 Thus, it is essential to recognize those patients with COVID-19 at the beginning of the visit or even in telemedicine visits. In this study, we provided evidence that long-lasting bilateral headaches over 48-72 hours and headaches resistant to analgesics suggested the likelihood of being infected by COVID-19 similar to other secondary headaches. The interesting distributions of pulsating and pressing characters in COVID-19 patients, as seen in Table 1, showed that pulsating type was more pronounced in patients with previous headaches; this may indicate that individual backgrounds are important in the final phenotypic presentation of COVID-related headache. COVID-19 infection may play a synergistic role in nociception using similar pathways of the trigeminovascular complex as the underlying primary headache such as migraine. However, different characteristics like pulsating, pressing, and even stabbing quality may indicate that more than one mechanism is involved in COVID-19 related headache emergence. A case report by a headache expert diagnosed with COVID-19 also indicated that several types of headaches can be seen during COVID-19 infection based on a single case (himself). 32 Our data had a cross-sectional design; and many participants have chosen only one type despite the availability of multiple choices. Another intriguing finding was that photophobia was more frequently experienced by infected participants than those without COVID-19, reaching statistical significance between the subgroups without prior headache. Moreover, osmophobia was more frequently seen in the group with COVID-19, which may also be related to the olfactory dysfunction. Further basic studies are needed to clarify the mechanism of COVID-19-related headache and to unravel the mysteries of the environmental factors including viruses for the headache mechanisms, to make the pandemic disaster an opportunity. Limitations and strengths of the study There are some limitations to this study. First of all, we investigated headache characteristics via questionnaire; the results were based on the answers of the patients, with the potential of a reporting bias well known in all survey studies. Secondly, the patients with COVID-19 were not examined by a physician or headache specialist. Furthermore, our questionnaire was a web-based survey, therefore, only individuals who were able to use new technological devices, thus probably younger and educated people could participate in the study. Among the participants, there may also be some patients who were not tested for COVID-19 due to the lack of other accompanying symptoms. Moreover, patients with severe COVID-19, at the time of the survey, could not be included. The main strength of our study was the participation of a large number of people in a very short time in the increasing phase of the pandemic. We used a detailed dedicated questionnaire investigating various characteristics of previous and current headaches, including also cross-questions to avoid misunderstandings. The answers given by participants were also examined meticulously to minimize discrepancies. Furthermore, the presence of healthcare workers, reaching nearly half of the participants has increased the reliability of the study. Conclusion The COVID-19 pandemic seems to have a particular effect on the characteristics and the course of headaches in individuals with and without COVID-19 diagnosis, according to our findings. We disclosed that having male gender, bilateral, long-lasting headaches, and resistance to analgesics were more frequently seen in people with COVID-19 infection in conjunction with anosmia/ageusia and gastrointestinal complaints, besides other infection findings. We propose that these features may be diagnostic for COVID-19 infection in the clinical evaluation of headache patients during the pandemic. We think that COVID-19 related headache should be considered as a separate entity, among the infection-related secondary headaches, with this different profile. Abbrevations COVID-19: Coronavirus disease 2019 SARS-CoV 2: Severe acute respiratory syndrome coronavirus 2 ACE-2: Angiotensin converting enzyme TNF- α: Tumor necrosis factor-α IL-1β: Interleukin-1β IL-6: Interleukin-6 IL-8: Interleukin-8 CGRP: Calcium gene related peptide TTH: Tension type headache ICD-3: International Classification of Headache Disorders, 3rd Edition PCR: Polymerase chain reaction MHC: Major histocompatibility complex RR: Relative risk ratio OR: Odds ratio GI: Gastrointestinal Declarations Consent for Publication: Not applicable Ethics Approval and consent to participate: Istanbul University Istanbul Faculty of Medicine Ethics Committee approved the study (17.04.2020/520). Availability of Data and Materials: This study is a web-based questionnaire, the data is not applicable. Funding: We received support from the Istanbul University Scientific Research Fund at the stages of creating web questionnaires and reaching patients (project number: GAP-36802). Declaration of interests: We declare no competing interests. Contributors HB, AO, EKO, EE, BB designed the survey. ME did statistical analyses. All authors drafted the manuscript. Acknowledgments : This study was funded by Scientific Research Projects Coordination Unit of Istanbul University with a project number of GAP-36802. The web and handy design of the questionnaire was delicately organized by Vedat Kamer, Sevinç Gülseçen and Başak Kurtuldu from Istanbul University Department of Informatics, to whom the authors are grateful. The authors also thank to the members of the Turkish Neurology Society Headache Group and Global Migraine and Pain Society for supporting the dissemination of the questionnaire. Funding: This study was funded by Istanbul University Scientific Research Fund with a project number of GAP-36802. References Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382 :1708-20. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020; 77 :1-9 Borges do Nascimento IJ, Cacic N, Abdulazeem HM, et al. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. J Clin Med 2020; 9 (4) Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368 :m1091. Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis 2020; 94 :81-7. Kaur N, Gupta I, Singh H, et al. Epidemiological and Clinical Characteristics of 6635 COVID-19 Patients: a Pooled Analysis). SN Compr Clin Med . 2020; 9 :1–5. Ozdag Acarli AN, Samanci B, Ekizoglu E, et al. Coronavirus Disease 2019 (COVID-19) From the Point of View of Neurologists: Observation of Neurological Findings and Symptoms During the Combat Against a Pandemic. Arch Neuropsychiat ry 2020; 57 :154-9. Pinzon RT, Wijaya VO, Buana RB et al. Neurologic Characteristics in Coronavirus Disease 2019(COVID-19): A Systematic Review and Meta-Analysis. Front Neurol . 2020; 11 : 565. Bolay H, Gul A, Baykan B. COVID-19 is a Real Headache! Headache. 2020; 60 :1415-21. Toptan T, Aktan C, Basari A, Bolay H. Case series of headache characteristics in COVID-19; Headache can be an isolated symptom. Headache 2020; 60 :1788-92. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38 :1-211. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection 2020; 48 :155-63. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8 :475-81. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. American Journal of Respiratory and Critical Care Medicine. 2020; 202 :756-59 Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020; 92 :568-76. Alon T, Doepke M, Olmstead-Rumsey J, Tertilt M. The Impact of COVID-19 on Gender Equality. Covid Economics, Vetted and Real-Time Papers. 2020;(4):62-85. Slowik A, Beyer C. Inflammasomes are neuroprotective targets for sex steroids. J Steroid Biochem Mol Biol. 2015; 153 :135-43. Bernstein KE, Khan Z, Giani JF, Cao DY, Bernstein EA, Shen XZ. Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol. 2018; 14 :325-36. Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004; 203 :622-30. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005; 202 :415-24. Izquierdo-Dominguez A, Rojas-Lechuga MJ, Mullol J, Alobid I. Olfactory dysfunction in the COVID-19 outbreak. J Investig Allergol Clin Immunol. 2020; 30 (5). doi: 10.18176/jiaci.0567. Online ahead of print Baysal-Kirac L, Uysal H. COVID-19 associate neurological complication. Neurol Sci Neurophysiol. 2020; 37 :1-3. Mengeling WL, Boothe AD, Ritchie AE. Characteristics of a coronavirus (strain 67N) of pigs. Am J Vet Res. 1972; 33 :297-308. Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dube M, et al. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses. 2020; 12 (1);14. hdoi.org/10.3390/v12010014 Huang C, Wang Y, Li X, R, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 :497-506. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020; 69 :1002-1009. Falkenberg K, Bjerg HR, Olesen J. Two-Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment. Headache. 2020; 60 :929-937. doi:10.1111/head.13795 Arca KN, Starling AJ. Treatment-RefractoryHeadachein the Setting of COVID 19 Pneumonia: Migraine or Meningoencephalitis? Case Report. SN Compr Clin Med. 2020 Jun 25:1-4. doi: 10.1007/s42399-020-00369-y. Online ahead of print. Korth J, Wilde B, Dolff S, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. J Clin Virol. 2020; 128 :104437. Sharon H Bergquist, Clyde Partin, David L Roberts, James B O'Keefe, Elizabeth J Tong, Jennifer Zreloff, Thomas L Jarrett, Miranda A Moore . Non-hospitalized Adults with COVID-19 Differ Noticeably from Hospitalized Adults in Their Demographic, Clinical, and Social Characteristics . SN Compr Clin Med. 2020 Aug 14;1-9.doi: 10.1007/s42399-020-00453-3. Online ahead of print. Baykan B, Ertas M, Karli N, et al. The burden of headache in neurology outpatient clinics in Turkey. Pain Pract. 2007; 7 :313-23. Belvis R. Headaches During COVID-19: My Clinical Case and Review of the Literature. Headache. 2020; 60 :1422-1426. Tables Table 1: Demographic features of participants and characteristics of headache experienced during the pandemic period (n=1968) COVID-19 positive* No COVID-19# Prior headache (n=116) No prior headache (n=87) p Prior headache (n=138) No prior headache (n=383) p p (1-3)† p (2-4)‡ Age year,mean (SD) 39.7 (11) 38.2 (11) .370 41.0 (10) 42.2 (11) .061 .175 .004 Sex (male %) 36.2 46.0 .104 22.9 31.6 .000 .001 .008 Healthcare worker (%) 44.0 43.7 .541 46.1 48.3 .239 .366 .255 Headache duration hours mean (SD) 52.1 (57) 45.3 (53) .430 38.4 (53) 45.9 (63) .039 .014 .949 Headache characteristics Pulsating % 50.9 32.5 .008 55.5 42.5 .000 .202 .064 Pressing % 31.9 43.7 .058 29.0 38.6 .000 .289 .227 Fiery % 2.6 2.3 .633 2.7 5.0 .022 .625 .219 Stabbing % 12.9 16.1 .330 11.1 11.2 .497 .315 .142 Accompanying symptoms Nausea % 70.8 71.3 .538 53.5 52.9 .450 .000 .002 Phonophobia % 67.0 67.9 .509 71.2 66.6 .056 .198 .465 Photophobia % 63.9 63.0 .508 60.5 51.2 .002 .276 .038 Osmophobia % 39.0 50.0 .090 30.4 28.5 .292 .044 .000 Allodynia % 31.9 - - 41.8 - - .024 - Anosmia/ageusia % 74.5 73.2 .479 19.1 23.1 .073 .000 .000 Sore throat, rhinorrhea % 62.2 70.4 .152 41.8 54.4 .000 .000 .006 Stinging, burning, tearing in the eyes 63.2 64.6 .481 44.8 49.8 .063 .000 .011 Use of analgesics % 84.3 79.8 .257 82.8 69.8 .000 .389 .042 No response to analgesics % 16.5 22.4 .227 7.1 8.0 .353 .002 .002 Partial response to analgesics 50% 32.0 25.4 .231 26.1 27.4 .362 .129 .436 Completely recovered with analgesics % 12.4 11.9 .568 39.2 26.2 .000 .000 .008 * Diagnosed by positive PCR test; # No COVID-19 symptoms or diagnosis; † p (1-3) p value between the patients with prior headache with or without positive COVID-19 test; ‡ p (2-4) p value between the patients with no prior headache with or without positive COVID-19 test (significant test values are marked as bold) Table 2: Odds ratios of differentiating variables of the headache in patients with COVID-19 diagnosis Headache characteristics COVID-19 positive n (%) No COVID-19 n (%) OR Presence of anosmia/ageusia 142(74%) 282(%20) 11.4 Bilateral headache 166 (85%) 994 (64%) 3.37 Analgesic-resistant 32(%18) 116(8%) 2.61 Gastrointestinal symptoms 137(70%) 808(53%) 2.13 Male gender 82(%40) 437(25%) 2.06 Headache duration >72 hours 27(13.3%) 130(7%) 1.93 Headache duration > 48 hours 55(27%) 328(18.5%) 1.63 Supplementary Files SupplementaryTable.docx Cite Share Download PDF Status: Published Journal Publication published 13 Oct, 2020 Read the published version in The Journal of Headache and Pain → Version 2 posted Editor assigned by journal 18 Sep, 2020 Editorial decision: Accept 18 Sep, 2020 Submission checks completed at journal 17 Sep, 2020 Editor invited by journal 17 Sep, 2020 You are reading this latest preprint version Show more versions Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-59636","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research article","associatedPublications":[],"authors":[{"id":2632211,"identity":"516d43d9-ed33-4a6e-8481-a15202f29031","order_by":0,"name":"Özge Uygun","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA3UlEQVRIiWNgGAWjYFAD9h4wxcNHvBaeMwwMB4AUG/FaJHLAWhgIauHnP/6AmbetNnG75NuDjz/m2MmwMTA/fHQDjxbJhgMJQC3HE3fOzks2OLgtGegwNmPjHDxaDA42HABqOZa44XaOmcTBbcxALTxs0ni1HGZsgGi5eQakpZ4ILceYGYBaahI33OABaTlMWItkDxsD45xzB4w3nMkxNji77TgPGzMBv4BCjOFNWZ3shuNnDB9Ubqu252dvfvgYnxYgYP/ByHYYic+MXzkU/KkjStkoGAWjYBSMUAAA3Y5GwCivFk0AAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0001-9786-5892","institution":"Istanbul Universitesi Istanbul Tip Fakultesi","correspondingAuthor":true,"prefix":"","firstName":"Özge","middleName":"","lastName":"Uygun","suffix":""},{"id":2632212,"identity":"2a722a1b-6ed0-40b4-bd20-02fd7065e574","order_by":1,"name":"Mustafa Ertas","email":"","orcid":"","institution":"Istanbul Universitesi Istanbul Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Mustafa","middleName":"","lastName":"Ertas","suffix":""},{"id":2632213,"identity":"c55606ae-5d5f-4572-afb7-9fa73e99cce7","order_by":2,"name":"Esme Ekizoğlu","email":"","orcid":"","institution":"Istanbul Universitesi Istanbul Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Esme","middleName":"","lastName":"Ekizoğlu","suffix":""},{"id":2632214,"identity":"2c877d88-d47d-440c-a493-273ca31ecee3","order_by":3,"name":"Hayrunnisa Bolay","email":"","orcid":"","institution":"Gazi Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Hayrunnisa","middleName":"","lastName":"Bolay","suffix":""},{"id":2632215,"identity":"7718a8b5-af84-475c-9625-e436696e9121","order_by":4,"name":"Aynur Özge","email":"","orcid":"","institution":"Mersin Universitesi Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Aynur","middleName":"","lastName":"Özge","suffix":""},{"id":2632216,"identity":"f24c05ec-08a1-4c4b-b151-5d0af9e979cd","order_by":5,"name":"Elif Kocasoy Orhan","email":"","orcid":"","institution":"Istanbul Universitesi Istanbul Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Elif","middleName":"Kocasoy","lastName":"Orhan","suffix":""},{"id":2632217,"identity":"a23a5ddb-fc4e-47c8-80ab-61e739202ec1","order_by":6,"name":"Arif Atahan Çağatay","email":"","orcid":"","institution":"Istanbul Universitesi Istanbul Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Arif","middleName":"Atahan","lastName":"Çağatay","suffix":""},{"id":2632218,"identity":"8a4d735c-0409-44f6-8392-4de6bb10f983","order_by":7,"name":"Betül Baykan","email":"","orcid":"","institution":"Istanbul Universitesi Istanbul Tip Fakultesi","correspondingAuthor":false,"prefix":"","firstName":"Betül","middleName":"","lastName":"Baykan","suffix":""}],"badges":[],"createdAt":"2020-08-14 12:13:22","currentVersionCode":2,"declarations":"","doi":"10.21203/rs.3.rs-59636/v2","doiUrl":"https://doi.org/10.21203/rs.3.rs-59636/v2","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1186/s10194-020-01188-1","type":"published","date":"2020-10-13T12:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":2566475,"identity":"f452f698-b9e2-433b-8ac3-b2c23b8f1058","added_by":"auto","created_at":"2020-09-23 22:27:38","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1116521,"visible":true,"origin":"","legend":": Flowchart of the study \n*Please note that some participants with previous headaches did not experience headache attacks during the pandemic (March-April 2020). \n**Only those participants with headache attacks during the pandemic could be included in the analyses, done in terms of before-after pandemic comparisons.\nM; male, F; female\n","description":"","filename":"figure1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-59636/v2/figure1.jpeg"},{"id":2566476,"identity":"266d8b7d-c833-4655-9f9e-f14da4dfe18f","added_by":"auto","created_at":"2020-09-23 22:27:38","extension":"jpeg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":507369,"visible":true,"origin":"","legend":"Reported triggers for headache were shown comparatively in COVID-19 positive and negative cases. The second part of the figure shows the triggers reported by healthcare workers compared to the others.\n\n\n*p:0.0006, ӿp:0.0002, †p:0.0001, ‡p:0.0015 showing statistically significant differences between each reported trigger in COVID-19 positive and negative patients; and p:0.049, p:0.0001, p:0.0001showing statistically significant difference between healthcare workers and others, with Pearson Chi Square Test.\n\n\n","description":"","filename":"figure2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-59636/v2/figure2.jpeg"},{"id":2566477,"identity":"3c118175-ccfe-4efe-b7bf-e1cb81660e7e","added_by":"auto","created_at":"2020-09-23 22:27:38","extension":"jpeg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":660746,"visible":true,"origin":"","legend":"The course of headache characteristics","description":"","filename":"figure3.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-59636/v2/figure3.jpeg"},{"id":2566478,"identity":"c8aaaeb7-5e2c-48bc-86ee-235cf4a638d4","added_by":"auto","created_at":"2020-09-23 22:27:38","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":606391,"visible":true,"origin":"","legend":"Odds ratios of differentiating variables related to the presence of headache in patients with COVID-19 diagnosis reporting headache during the pandemic ","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-59636/v2/Figure4.jpg"},{"id":13596218,"identity":"963206e7-4040-46aa-b82d-a18922ebe803","added_by":"auto","created_at":"2021-09-17 05:27:33","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":591767,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-59636/v2/c265d42d-cd0e-4f72-8509-e616bffc5790.pdf"},{"id":2566480,"identity":"618a4373-c67f-4a73-87e0-5335ca7b0772","added_by":"auto","created_at":"2020-09-23 22:27:38","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":13395,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTable.docx","url":"https://assets-eu.researchsquare.com/files/rs-59636/v2/SupplementaryTable.docx"}],"financialInterests":"","formattedTitle":"\u003cp\u003eHeadache Characteristics In COVID-19 Pandemic-A Survey Study\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eCoronavirus disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) first emerged in Wuhan towards the end of 2019.\u003csup\u003e1\u003c/sup\u003e The pandemic is now influencing the whole world with a large number of deaths, besides many other medical and social consequences. The most common clinical picture of COVID-19 is characterized by manifestations of the respiratory system, as the name of the virus implies. However, many other complaints such as anosmia, ageusia, diarrhea and also headache have been noted in the clinical spectrum, with an increasing number of patients.\u003csup\u003e2\u003c/sup\u003e A handful of reports disclosed that headache is among the COVID-19-related symptoms, showing highly variable rates across the studies.\u003csup\u003e3-6\u003c/sup\u003e\u003c/p\u003e\n\u003cp\u003eThere are some studies and reviews highlighting that the most common neurological symptom is headache, often accompanied by high fever, moreover headache can occasionally be seen alone as the first sign of the disease.\u003csup\u003e2, 7\u003c/sup\u003e A recent meta-analysis reported that the prevalence of headache was 10.9% with a high level of heterogeneity.\u003csup\u003e8\u003c/sup\u003e \u0026nbsp;Therefore, detailed questioning of the presence of headaches in patients who are admitted to the emergency and outpatient departments is still an important step in the prompt recognition of the infection in some patients.\u003c/p\u003e\n\u003cp\u003eIn clinical observations and small case series, COVID-19 related headache was described as acute at onset, usually occurring in a different character unlike previous headaches.\u003csup\u003e9, 10\u003c/sup\u003e However, there are no systematic data on the headache characteristics.\u003c/p\u003e\n\u003cp\u003eAnother important problem is the situation of patients with previous severe headaches like migraine in the COVID-19 pandemic era. COVID-19 itself or its psycho-sociological effects may cause more headache burden, along with the problems of quarantine and these points are not yet investigated thoroughly.\u003c/p\u003e\n\u003cp\u003eIn this study, we aimed to reveal COVID-19 related headache characteristics and its associations. Our secondary aims were to investigate the features and course of pre-existing headaches as well as new-onset ones in participants without COVID-19 but having headaches during the pandemic.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003cu\u003eDesign of a web-based questionnaire \u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eAfter the emergence of COVID-19 for the first time in March 2020 in our country, the complaints of peculiar headaches in consulted cases and some distinctive headache features in admitted patients attracted our attention. For this reason, a detailed questionnaire was developed focusing on headache characteristics, besides some clinical COVID-19 features by a panel of headache experts, after rounds of online discussions. \u003cbr /\u003e The number of the questions was tried to be kept in an acceptable limit to optimize the attention during answering the survey and the survey was tested before its submission by five patients for clarity of the questions. The web-based, user-friendly technical design was planned by the experts of the Istanbul University Department of Informatics.\u003c/p\u003e\n\u003cp\u003eThe features of previous headaches were screened and headache diagnosis was made according to International Classification of Headache Disorders, 3\u003csup\u003erd\u003c/sup\u003e version (ICHD-3 criteria).\u003csup\u003e11\u003c/sup\u003e Possible changes in the headache course during the pandemic along with perceived precipitating factors and related characteristics were queried with scrutiny. Important characteristics such as the duration, frequency, course, localization, the severity of headaches, and treatment response were asked separately before and during the COVID-19 pandemic. The questionnaire has also asked if the participant had been diagnosed with COVID-19 as well as the symptoms of COVID-19 infection in detail for relevant patients. Even if the patient was not diagnosed with COVID-19, factors secondary to the pandemic lifestyle as possible triggers of headache, such as wearing a mask, having the fear of infection, etc. were evaluated. The questionnaire has included a total of 39 questions, and based on four different parts, in terms of demographics, previous headache features, reported COVID-19 infection features, and details of the headache course after the pandemic.\u003c/p\u003e\n\u003cp\u003eThe participants were invited by means of social media (using Twitter, Instagram or Whatsapp) using a web-based link, suitable also for smart phones, after the Ethics Committee approval (17.04.2020/520). Discharged COVID-19 patients of the Istanbul University Faculty of Medicine Hospital were invited by text messages to volunteer the survey, in order to increase the number of patients with COVID-19 infection-related headache.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eInclusion and exclusion criteria \u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eEligible participants older than 18\u003cspan style=\"text-decoration: line-through;\"\u003e-\u003c/span\u003eyears who had a COVID-19 infection experiencing headache among their symptoms or who had any type of headache before the pandemic, or developed new-onset headaches were included. The volunteers who participated in the survey were grouped according to being diagnosed with COVID-19 infection or not. In our country\u0026rsquo;s protocol, only those patients who have polymerase chain reaction (PCR) positivity, are diagnosed with COVID-19. Especially, healthcare workers were encouraged to attend the study. Figure 1 shows the flowchart of our study. Surveys completed by participants under age of 18 or those reporting inconsistent responses were excluded. Participants without headache during the pandemic were not included in the statistical analysis.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eStudy period\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eThe duration of survey implementation was planned as 15 days, starting on 1 May 2020. Although reaching a high number in a few hours, the survey was continued to the end of this period to include more patients with COVID-19 related headaches.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eStatistical analysis\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eDescriptive analyses were applied for four main groups of participants (Figure 1, Table 1); the participants with or without COVID-19 were compared in relation to the presence or absence of previous headaches before the pandemic of COVID-19 in regard to headache characteristics by the chi-square test and t-test where appropriate. A binary logistic regression model was performed to explore the differentiating headache variables between COVID-19 positive and negative cases. The odds ratios were calculated for significant infection-related features, such as anosmia/ageusia and gastrointestinal complaints like diarrhea. IBM SPSS Statistics Version 22 was used and p\u0026lt;0.05 was considered as statistically significant.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eA total of 3458 participants (2341 females) contributed to our survey. Of this main group with and without headache during the pandemic, 262 patients were diagnosed with COVID-19 by PCR (Figure 1). These 262 patients were grouped as COVID-19 positive including 136 females (51.9%) and 89 healthcare workers (9.8%).\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eThe characteristics of patients with COVID-19 infection \u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eIn the COVID-19 positive group, the rate of males was 48.1% (126 out of 262 patients), whereas in the COVID-19 negative group this rate was 31% (991 out of 3196 participants), showing a significant gender difference (p\u0026lt;0.000). Headaches lasting over 72 hours were reported by 10.3% (27 out of 262 participants) of COVID-19 infected patients versus 4.1% (130 out of 3196 participants) of the COVID-19 negative group (p\u0026lt;0.000).\u003c/p\u003e\n\u003cp\u003eIn this study, 1968 participants with or without COVID-19 infection reported headache attacks during the pandemic. Among them 714 (36.3%) had migraine and 1077 (54.7%) participants were diagnosed with tension type headache (TTH) according to ICHD-3 criteria. The headache characteristics, accompanying features, treatment responses of these patients experiencing headache during the pandemic, according to having or not having prior headaches were shown in Table 1, comparatively. Osmophobia was more frequently reported in the group with COVID-19. Most of the COVID-19 cases (71%) experienced nausea and gastrointestinal symptoms, for example, diarrhea/stomachache were present in more than half of them. Interestingly, pulsating quality was more pronounced in patients with previous headaches in the group with COVID-19 in comparison to the group with history of new onset headache.\u003c/p\u003e\n\u003cp\u003eThe great majority of COVID-19 patients with previous headaches (79.5%, 89 out of 112 responders) reported that their new emerging headaches during the infection period were different from their usual headaches; among them, 50% (56 participants) disclosed that this new headache was totally different, whereas 29.5% (33 participants) reported some differences despite some similar properties resembling previous headache features. On the other hand, among the participants without COVID-19 diagnosis but with previous headaches, 62.7% (785 out of 1252 responders) disclosed that their headaches were identical to the pre-existing episodes. Among them, only 13.9% (174 participants) reported entirely different attacks, whereas 23.4% (293 participants) reported partly different headaches.\u003c/p\u003e\n\u003cp\u003eSeverity of the previous headaches did not relate to receiving COVID-19 diagnosis; COVID-19 positive patients had reported headaches of mild intensity in 26.6% (34 out of 128 responders), moderate-intensity in 47.7% (61 participants), severe in 23.4% and very severe (dependent to bed/hospital) in 2.3% (3 participants). The corresponding rates of headache intensity were 27.7% (484 out of 1747 responders), 46.7% (816 participants), 21% (367 participants), and 4.6% (80 participants) in COVID-19 negative participants.\u003c/p\u003e\n\u003cp\u003eAmong all 262 patients diagnosed with COVID-19, 40% (104 participants) reported high fever (over 38˚C), 49.2% (128 participants) prominent cough, 48.3% (125 participants) sore throat and 33.5% (87 participants) shortness of breath. On the other hand, diarrhea/stomachache was present in 57.7% (150 participants) and lastly anosmia/ageusia was present in 60.4% (157 participants) of this group. There were 59 (22.5%) COVID-19 positive patients who had previous headaches, who did not experience headaches during the pandemic period of 2 months at the time of their participation in the survey. At least one close contact with the disease was present in 65.4% (170 participants) of the COVID-19 positive patients and 90.1% of the patients lived under quarantine.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eTriggers of headache in the study population\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eThe triggers of headache reported by the participants are shown comparatively in COVID-19 positive and negative cases in the Figure 2; the second part of this figure shows the triggers reported by healthcare workers compared to the others. We noticed that stress was the most common trigger up to 30% of the participants as seen as in the Figure 2 and social isolation triggered headache noteworthy in patients without COVID-19. On the other hand, the patients diagnosed with COVID-19 reported also infection itself and the drugs as triggers of headache.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003e\u0026nbsp;The course of headache in participants during the pandemic\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eThe reported changes in the headache course after the pandemic were shown in Figure 3. Among the responding 1886 patients, 23.3% reported an increase in severity of headache, 28.7% reported an increase of the headache duration, and lastly 14% reported deterioration in the accompanying symptoms. The decreased headache frequency in 12.3% of the group was remarkable.\u003c/p\u003e\n\u003cp\u003eOur analysis showed that among the patients with pre-existing migraine diagnosis, the frequency of pulsating headache character decreased from 60.5% (328 out of 542 pts) to 55% (22 out of 40 pts) in those receiving COVID-19 diagnosis. However, this latter rate was still significantly higher in comparison to 34.1% (31 out of 91 pts) compared to COVID-19 positive patients without previous headache (p=0.033).\u003c/p\u003e\n\u003cp\u003eThe worsening of previous headache and analgesic unresponsiveness did not show any difference in relation to ages of the participants with COVID-19.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eDifferentiating variables of COVID-19 related headache \u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eThe important differentiating variables for COVID-19 infection patients suffering from headaches were summarized in Table 2 and graphed as Figure 4, with calculated Odds ratios (OR). According to our findings, the presence of bilateral headache, duration over 72 hours, male gender, analgesic resistance, gastrointestinal symptoms and anosmia/ageusia showed increased risk of having headache related to COVID-19 infection.\u003c/p\u003e\n\u003cp\u003eAdditionally, binary logistic regression was computed with significant headache variables which could be observed in everyday practice to distinguish COVID-19 related headaches. The model summary showed a -2 Log likelihood ratio of 1003.6 (Nagelkerke R Square: 0.105) and using this model 88.6% of the COVID-19 patients could be classified correctly with a cut off value of 0.5. We did not enter infection-related features in this analysis, because they are clear clues for COVID-19 and do not appear in control cases. Our findings disclosed that bilateral headache, duration over 72 hours, male gender, and analgesic resistance were important variables to differentiate between COVID-19 positive patients from negative ones, showing statistical levels as p=0.04 for long duration of headaches and p\u0026lt;0.000 for the remaining variables (Supplementary Table 1).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis first careful analysis of emerging headache characteristics in the pandemic showed that COVID-19 related headaches are more closely associated with anosmia/ageusia and gastrointestinal complaints, in comparison to other usual infection findings. Moreover, bilateral headache, duration over 72 hours, male gender, and analgesic resistance are highly important variables to differentiate between COVID-19 positive patients from negative ones. Although we expected prominent worsening of primary headaches due to the pandemic-related problems, this happened only for less than 1/3 of participants, mostly related to stress.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eGender difference of COVID-19 related headaches \u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eDespite the well-known predominance of headaches in females and the fact that more than 2/3 of participants answering our survey consisted of females, COVID-19 related headaches were reported by male patients at a high rate. This interesting finding is somewhat in line with the predominance of COVID-19 in male gender, with changing reported rates around 56-73%.\u003csup\u003e12-14\u003c/sup\u003e It could be hypothesized that this reversed gender dominance may relate to comorbidities like atherosclerosis and hypertension which are more frequent in males. However, females with nearly three times higher rates of migraine could still have outnumbered in COVID-19 related headaches.\u003csup\u003e12,15\u003c/sup\u003e Therefore, this finding is a striking point that needs further careful elaboration. Given the higher risk of male gender in COVID-19 cases, a protective role of female hormones or of the location of Angiotensin-converting enzyme 2 (ACE-2) on the X chromosome could be speculated.\u003csup\u003e9,12\u003c/sup\u003e Moreover, ACE-2 expression level which is critical for the SARS- CoV-2 entry to the cells was found different between genders.\u003csup\u003e14\u003c/sup\u003e There is some evidence that immune activity is more efficient in females in other viral infections.\u003csup\u003e16\u003c/sup\u003e It is tempting to speculate that SARS-CoV-2 may trigger some silenced genes related to innate immunity in the X chromosome, so two X chromosomes may serve for a more effective and balanced war against COVID-19 related hyperactivation of immune pathways. Moreover, estrogens and progesterone have anti-inflammatory actions partially through inflammasome activation in some models.\u003csup\u003e17\u003c/sup\u003e ACE also affects the display of major histocompatibility complex (MHC) class I and MHC class II peptides.\u003csup\u003e18\u003c/sup\u003e Thus, further work with these gender-related differences may give us some clues to find out novel protective ways against COVID-19.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003ePossible mechanisms underlying COVID-19 related headaches in the light of our findings\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eThe underlying mechanisms of headache related to COVID-19 are not clear at this early moment.\u003csup\u003e9\u003c/sup\u003e A direct invasion of trigeminal nerve endings in the nasal or oral cavity by the virus seems one of the most reasonable mechanisms underlying headache according to our results showing the close relation between headache and anosmia/ageusia. Some coronaviruses were shown to be neurotropic and former SARS‐CoV has been observed in the human brain.\u003csup\u003e19,20\u003c/sup\u003e Therefore, it is highly likely that SARS‐CoV‐2 may also enter the nervous system via the cranial nerves. Since the first observations in China, there are many worldwide reports showing heterogeneous prevalence figures around 5-85% of loss of smell.\u003csup\u003e21, 22\u003c/sup\u003e These profound differences may relate to the viral load differences and a different individual immune response between younger milder symptomatic outpatients, who are eager to report their symptoms, and contrarily severe COVID-19 inpatients with prominent respiratory problems who probably under-report this relatively milder problem. It is well-known that methodological differences exist between questionnaire studies and objective measurements, the former being mostly with lower prevalence. Despite this fact, the rate of anosmia/ageusia was high in our study. These two distinct problems caused by different nerves were not easy to differentiate from each other in daily life, therefore anosmia and ageusia were evaluated together in our study. It was remarkable that nasal obstruction and rhinorrhea were frequently reported but not strictly correlated with anosmia and ageusia according to our results. Although the trans‐synaptic transfer of SARS-COV-2 is not proven yet, this possibility of the trans‐synaptic route was documented for other coronaviruses.\u003csup\u003e23\u003c/sup\u003e Entrance from the nasal cavity to the olfactory bulb, then spreading to the brainstem via the piriform cortex with both passive diffusion and axonal transport has been demonstrated.\u003csup\u003e24\u003c/sup\u003e\u003c/p\u003e\n\u003cp\u003eBesides the described headache characteristics and COVID-19 related respiratory tract symptoms, abdominal pain and diarrhea should be taken into account to evaluate these patients.\u003csup\u003e3-5,25\u003c/sup\u003e Our study found a high rate of gastrointestinal symptoms like diarrhea/stomachache in more than half of the COVID-19 cases and also high rates of nausea (71%) as an accompanying symptom of headache. A previous interesting report from China on non-classical symptoms indicated that 21.6% of patients had gastrointestinal symptoms, associated with headache, which is a higher number in comparison to patients without gastrointestinal symptoms.\u003csup\u003e26\u003c/sup\u003e The intriguing relationship of headache with gastrointestinal symptoms also brings to mind several interesting mechanisms including increased circulating Calcium gene related peptide (CGRP) levels and \u0026ldquo;gut-brain axis\u0026rdquo; concept where several inflammatory mediators like Interleukin-1\u0026beta; (IL-1 \u0026beta;), Interleukin-6 (IL-6), Interleukin-8 (IL-8), and Tumor necrosis factor-\u0026alpha; (TNF-\u0026alpha;), besides gut microbiota, and neuropeptides including CGRP are thought to play a role in this interaction. Another relevant consideration is systemic CGRP increase, possibly induced by both angiotensin II and IL-6 levels, as CGRP is clearly associated with trigemino vascular activation resulting in headache, increased gastrointestinal (GI) motility leading to diarrhea, further triggering inflammation and vascular edema.\u003csup\u003e9,27\u003c/sup\u003e Taken together with the unusually high rate of ageusia-anosmia (60.4%), this data may lead us to the footsteps of the viral pathway in the brain. Thus, we may also suggest that neuronal invasion of this new coronavirus may cause the dysfunction of the network at brainstem sites, in addition to headache. Nausea and vomiting are associated GI symptoms of migraine headache, yet the diarrhea is a distinct GI feature associated with headache in COVID-19, which clearly shows that opposite influencers play role in SARS-CoV-2 infected gut and trigeminal nerve.\u003c/p\u003e\n\u003cp\u003eHeadache in relation with a systemic viral infection, (without signs of meningo-encephalitis) is described in the International Classification of Headache Disorders-3. The underlying mechanisms of this entity are not illuminated so far. Regarding its characteristics, diffuse pain of moderate/severe intensity, commonly with fever was noted.\u003csup\u003e11\u003c/sup\u003e However, in our analyses, the association of headache with fever seems not to be decisive (in all COVID-19 patients with headache, only 40% reported high fever). Also, rhinosinusitis and other respiratory tract symptoms did not seem to explain the headaches in many of these cases, as seen in Table 1. Therefore, for this emerging COVID-19 related headache, the simplistic view of a \"causal\" relationship with fever or upper respiratory symptoms is not explanatory.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eThe course of headaches during the pandemic and reported triggers for headache\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eMost of the patients with pre-existing headaches easily noticed that this was a different problem if they had COVID-19 related headache according to our survey. In a recent case report, the authors highlighted the need to consider secondary headaches, related to central nervous system infections in the setting of COVID-19 in patients experiencing refractory headache, even if the patient had chronic migraine.\u003csup\u003e28\u003c/sup\u003e On the other hand, it was also intriguing that 22.5% of the COVID-19 positive cases with previous headaches did not suffer from headache during the pandemic and during the infection. There is no clear explanation for the lack of headache in these cases; causes related to viral load, transmission route, or individual differences may play a role. Other interesting data were the stabile course (53%) or even decrease of the attack frequencies (12%) and reduced severity of the pre-existing headaches in the pandemic period despite the apparent stressful conditions. Social isolation may have helped to avoid stressful social interactions; a healthy diet, and mild sports activities are possible with spending more time at home, also reducing the stress of daily-work life during the pandemic; all these points were possible reasons for the better headache outcome than expected.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe triggers for headaches showed significant differences between participants with and without COVID-19 infection. Headache was triggered more frequently by stress and social isolation in patients without COVID-19 whereas patients diagnosed with COVID-19 reported also infection itself and the drugs as triggers of headache. Furthermore, wearing masks as well as stress both were the main triggers of headache and were more frequently reported by healthcare workers than by the others. Standard hygiene precautions seemed to reduce the risk for the healthcare workers who did not show an increased risk for COVID-19 compared to other participants in our study. It was reported from Germany that an overall seroprevalence of SARS-CoV-2 in a tertiary hospital was low, given the standard hygiene measures taken.\u003csup\u003e29\u003c/sup\u003e\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eOther differentiating features and associations of COVID-19 related headache \u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eThe clinical features of COVID-19 infection in non-hospitalized adults were reported to be different from hospitalized patients warranting greater awareness of this wider spectrum of clinical symptoms.\u003csup\u003e30\u003c/sup\u003e Headache as the leader of the COVID-19 related neurological symptoms is the most frequent complaint in outpatient clinics.\u003csup\u003e31\u003c/sup\u003e Thus, it is essential to recognize those patients with COVID-19 at the beginning of the visit or even in telemedicine visits. In this study, we provided evidence that long-lasting bilateral headaches over 48-72 hours and headaches resistant to analgesics suggested the likelihood of being infected by COVID-19 similar to other secondary headaches. The interesting distributions of pulsating and pressing characters in COVID-19 patients, as seen in Table 1, showed that pulsating type was more pronounced in patients with previous headaches; this may indicate that individual backgrounds are important in the final phenotypic presentation of COVID-related headache. COVID-19 infection may play a synergistic role in nociception using similar pathways of the trigeminovascular complex as the underlying primary headache such as migraine. However, different characteristics like pulsating, pressing, and even stabbing quality may indicate that more than one mechanism is involved in COVID-19 related headache emergence. A case report by a headache expert diagnosed with COVID-19 also indicated that several types of headaches can be seen during COVID-19 infection based on a single case (himself).\u003csup\u003e32\u003c/sup\u003e Our data had a cross-sectional design; and many participants have chosen only one type despite the availability of multiple choices. Another intriguing finding was that photophobia was more frequently experienced by infected participants than those without COVID-19, reaching statistical significance between the subgroups without prior headache. Moreover, osmophobia was more frequently seen in the group with COVID-19, which may also be related to the olfactory dysfunction. Further basic studies are needed to clarify the mechanism of COVID-19-related headache and to unravel the mysteries of the environmental factors including viruses for the headache mechanisms, to make the pandemic disaster an opportunity.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003eLimitations and strengths of the study\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003eThere are some limitations to this study. First of all, we investigated headache characteristics via questionnaire; the results were based on the answers of the patients, with the potential of a reporting bias well known in all survey studies. Secondly, the patients with COVID-19 were not examined by a physician or headache specialist. Furthermore, our questionnaire was a web-based survey, therefore, only individuals who were able to use new technological devices, thus probably younger and educated people could participate in the study. Among the participants, there may also be some patients who were not tested for COVID-19 due to the lack of other accompanying symptoms. Moreover, patients with severe COVID-19, at the time of the survey, could not be included.\u003c/p\u003e\n\u003cp\u003eThe main strength of our study was the participation of a large number of people in a very short time in the increasing phase of the pandemic. We used a detailed dedicated questionnaire investigating various characteristics of previous and current headaches, including also cross-questions to avoid misunderstandings. The answers given by participants were also examined meticulously to minimize discrepancies. Furthermore, the presence of healthcare workers, reaching nearly half of the participants has increased the reliability of the study.\u0026nbsp;\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThe COVID-19 pandemic seems to have a particular effect on the characteristics and the course of headaches in individuals with and without COVID-19 diagnosis, according to our findings. We disclosed that having male gender, bilateral, long-lasting headaches, and resistance to analgesics were more frequently seen in people with COVID-19 infection in conjunction with anosmia/ageusia and gastrointestinal complaints, besides other infection findings. We propose that these features may be diagnostic for COVID-19 infection in the clinical evaluation of headache patients during the pandemic. We think that COVID-19 related headache should be considered as a separate entity, among the infection-related secondary headaches, with this different profile.\u003c/p\u003e"},{"header":"Abbrevations","content":"\u003cp\u003eCOVID-19: Coronavirus disease 2019\u003c/p\u003e\n\u003cp\u003eSARS-CoV 2: Severe acute respiratory syndrome\u0026nbsp;coronavirus 2\u003c/p\u003e\n\u003cp\u003eACE-2: Angiotensin converting enzyme\u003c/p\u003e\n\u003cp\u003eTNF- \u0026alpha;: Tumor necrosis factor-\u0026alpha;\u003c/p\u003e\n\u003cp\u003eIL-1\u0026beta;: Interleukin-1\u0026beta;\u003c/p\u003e\n\u003cp\u003eIL-6: Interleukin-6\u003c/p\u003e\n\u003cp\u003eIL-8: Interleukin-8\u003c/p\u003e\n\u003cp\u003eCGRP: Calcium gene related peptide\u003c/p\u003e\n\u003cp\u003eTTH: Tension type headache\u003c/p\u003e\n\u003cp\u003eICD-3: International Classification of Headache Disorders, 3rd Edition\u003c/p\u003e\n\u003cp\u003ePCR: Polymerase chain reaction\u003c/p\u003e\n\u003cp\u003eMHC: Major histocompatibility complex\u003c/p\u003e\n\u003cp\u003eRR: Relative risk ratio\u003c/p\u003e\n\u003cp\u003eOR: Odds ratio\u003c/p\u003e\n\u003cp\u003eGI: Gastrointestinal\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eConsent for Publication:\u003c/p\u003e\n\u003cp\u003eNot applicable\u003c/p\u003e\n\u003cp\u003eEthics Approval and consent to participate:\u003c/p\u003e\n\u003cp\u003eIstanbul University Istanbul Faculty of Medicine Ethics Committee approved the study (17.04.2020/520).\u003c/p\u003e\n\u003cp\u003eAvailability of Data and Materials:\u003c/p\u003e\n\u003cp\u003eThis study is a web-based questionnaire, the data is not applicable.\u003c/p\u003e\n\u003cp\u003eFunding:\u003c/p\u003e\n\u003cp\u003eWe received support from the Istanbul University Scientific Research Fund at the stages of creating web questionnaires and reaching patients (project number: GAP-36802).\u003c/p\u003e\n\u003cp\u003eDeclaration of interests:\u003c/p\u003e\n\u003cp\u003eWe declare no competing interests.\u003c/p\u003e\n\u003cp\u003eContributors\u003c/p\u003e\n\u003cp\u003eHB, AO, EKO, EE, BB designed the survey. ME did statistical analyses. All authors drafted the manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cu\u003eAcknowledgments\u003c/u\u003e\u003c/strong\u003e: This study was funded by Scientific Research Projects Coordination Unit of Istanbul University with a project number of GAP-36802. The web and handy design of the questionnaire was delicately organized by Vedat Kamer, Sevin\u0026ccedil; G\u0026uuml;lse\u0026ccedil;en and Başak Kurtuldu from Istanbul University Department of Informatics, to whom the authors are grateful. The authors also thank to the members of the Turkish Neurology Society Headache Group and Global Migraine and Pain Society for supporting the dissemination of the questionnaire.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding: \u003c/strong\u003eThis study was funded by Istanbul University Scientific Research Fund with a project number of GAP-36802.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eGuan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. \u003cem\u003eN Engl J Med\u003c/em\u003e 2020;\u003cstrong\u003e382\u003c/strong\u003e:1708-20.\u003c/li\u003e\n\u003cli\u003eMao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. \u003cem\u003eJAMA Neurol\u003c/em\u003e 2020;\u003cstrong\u003e77\u003c/strong\u003e:1-9\u003c/li\u003e\n\u003cli\u003eBorges do Nascimento IJ, Cacic N, Abdulazeem HM, et al. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. \u003cem\u003eJ Clin Med\u003c/em\u003e 2020;\u003cstrong\u003e9\u003c/strong\u003e(4)\u003c/li\u003e\n\u003cli\u003eChen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. \u003cem\u003eBMJ\u003c/em\u003e 2020; \u003cstrong\u003e368\u003c/strong\u003e:m1091.\u003c/li\u003e\n\u003cli\u003eZhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings.\u003cem\u003e Int J Infect Dis\u003c/em\u003e 2020;\u003cstrong\u003e94\u003c/strong\u003e:81-7.\u003c/li\u003e\n\u003cli\u003eKaur N, Gupta I, Singh H, et al. Epidemiological and Clinical Characteristics of 6635 COVID-19 Patients: a Pooled Analysis). \u003ca href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343407/\"\u003e\u003cem\u003eSN Compr Clin Med\u003c/em\u003e\u003c/a\u003e\u003cem\u003e. \u003c/em\u003e2020;\u003cstrong\u003e9\u003c/strong\u003e:1\u0026ndash;5.\u003c/li\u003e\n\u003cli\u003eOzdag Acarli AN, Samanci B, Ekizoglu E, et al. Coronavirus Disease 2019 (COVID-19) From the Point of View of Neurologists: Observation of Neurological Findings and Symptoms During the Combat Against a Pandemic. \u003cem\u003eArch Neuropsychiat\u003c/em\u003ery 2020;\u003cstrong\u003e57\u003c/strong\u003e:154-9.\u003c/li\u003e\n\u003cli\u003ePinzon RT, Wijaya VO, Buana RB et al. Neurologic Characteristics in Coronavirus Disease 2019(COVID-19): A Systematic Review and Meta-Analysis. \u003ca href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273516/\"\u003e\u003cem\u003eFront Neurol\u003c/em\u003e\u003c/a\u003e\u003cem\u003e.\u003c/em\u003e 2020;\u003cstrong\u003e11\u003c/strong\u003e: 565.\u003c/li\u003e\n\u003cli\u003eBolay H, Gul A, Baykan B. COVID-19 is a Real Headache! \u003cem\u003eHeadache.\u003c/em\u003e 2020;\u003cstrong\u003e60\u003c/strong\u003e:1415-21.\u003c/li\u003e\n\u003cli\u003eToptan T, Aktan C, Basari A, Bolay H. Case series of headache characteristics in COVID-19; Headache can be an isolated symptom. \u003cem\u003eHeadache\u003c/em\u003e 2020;\u003cstrong\u003e60\u003c/strong\u003e:1788-92.\u003c/li\u003e\n\u003cli\u003eHeadache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. \u003cem\u003eCephalalgia\u003c/em\u003e 2018;\u003cstrong\u003e38\u003c/strong\u003e:1-211.\u003c/li\u003e\n\u003cli\u003eCheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. \u003cem\u003eInfection\u003c/em\u003e 2020;\u003cstrong\u003e48\u003c/strong\u003e:155-63.\u003c/li\u003e\n\u003cli\u003eYang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. \u003cem\u003eLancet Respir Med\u003c/em\u003e 2020;\u003cstrong\u003e8\u003c/strong\u003e:475-81.\u003c/li\u003e\n\u003cli\u003eZhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. \u003cem\u003eAmerican Journal of Respiratory and Critical Care Medicine.\u003c/em\u003e 2020;\u003cstrong\u003e202\u003c/strong\u003e:756-59\u003c/li\u003e\n\u003cli\u003eWang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. \u003cem\u003eJ Med Virol.\u003c/em\u003e 2020;\u003cstrong\u003e92\u003c/strong\u003e:568-76.\u003c/li\u003e\n\u003cli\u003eAlon T, Doepke M, Olmstead-Rumsey J, Tertilt M. The Impact of COVID-19 on Gender Equality. \u003cem\u003eCovid Economics, Vetted and Real-Time Papers.\u003c/em\u003e 2020;(4):62-85.\u003c/li\u003e\n\u003cli\u003eSlowik A, Beyer C. Inflammasomes are neuroprotective targets for sex steroids. J\u003cem\u003e Steroid Biochem Mol Biol.\u003c/em\u003e 2015;\u003cstrong\u003e153\u003c/strong\u003e:135-43.\u003c/li\u003e\n\u003cli\u003eBernstein KE, Khan Z, Giani JF, Cao DY, Bernstein EA, Shen XZ. Angiotensin-converting enzyme in innate and adaptive immunity. \u003cem\u003eNat Rev Nephrol.\u003c/em\u003e 2018;\u003cstrong\u003e14\u003c/strong\u003e:325-36.\u003c/li\u003e\n\u003cli\u003eDing Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. \u003cem\u003eJ Pathol.\u003c/em\u003e 2004;\u003cstrong\u003e203\u003c/strong\u003e:622-30.\u003c/li\u003e\n\u003cli\u003eGu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. \u003cem\u003eJ Exp Med.\u003c/em\u003e 2005;\u003cstrong\u003e202\u003c/strong\u003e:415-24.\u003c/li\u003e\n\u003cli\u003eIzquierdo-Dominguez A, Rojas-Lechuga MJ, Mullol J, Alobid I. Olfactory dysfunction in the COVID-19 outbreak. J\u003cem\u003e Investig Allergol Clin Immunol.\u003c/em\u003e 2020;\u003cstrong\u003e30\u003c/strong\u003e(5). doi: 10.18176/jiaci.0567. Online ahead of print\u003c/li\u003e\n\u003cli\u003eBaysal-Kirac L, Uysal H. COVID-19 associate neurological complication. \u003cem\u003eNeurol Sci Neurophysiol.\u003c/em\u003e 2020;\u003cstrong\u003e37\u003c/strong\u003e:1-3.\u003c/li\u003e\n\u003cli\u003eMengeling WL, Boothe AD, Ritchie AE. Characteristics of a coronavirus (strain 67N) of pigs. \u003cem\u003eAm J Vet Res.\u003c/em\u003e 1972;\u003cstrong\u003e33\u003c/strong\u003e:297-308.\u003c/li\u003e\n\u003cli\u003eDesforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dube M, et al. Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? \u003cem\u003eViruses. \u003c/em\u003e2020;\u003cstrong\u003e12\u003c/strong\u003e(1);14. \u003ca href=\"https://doi.org/10.3390/v12010014\"\u003ehdoi.org/10.3390/v12010014\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003eHuang C, Wang Y, Li X, R, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. \u003cem\u003eLancet.\u003c/em\u003e 2020;\u003cstrong\u003e395\u003c/strong\u003e:497-506.\u003c/li\u003e\n\u003cli\u003eJin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. \u003cem\u003eGut.\u003c/em\u003e 2020;\u003cstrong\u003e69\u003c/strong\u003e:1002-1009.\u003c/li\u003e\n\u003cli\u003eFalkenberg K, Bjerg HR, Olesen J. Two-Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment. \u003cem\u003eHeadache.\u003c/em\u003e 2020;\u003cstrong\u003e60\u003c/strong\u003e:929-937. doi:10.1111/head.13795\u003c/li\u003e\n\u003cli\u003eArca KN, Starling AJ. Treatment-RefractoryHeadachein the\u0026nbsp;Setting\u0026nbsp;of\u0026nbsp;COVID 19\u0026nbsp;Pneumonia:\u0026nbsp;Migraine\u0026nbsp;or\u0026nbsp;Meningoencephalitis?\u0026nbsp;Case\u0026nbsp;Report. SN Compr Clin Med. 2020 Jun 25:1-4. doi: 10.1007/s42399-020-00369-y. Online ahead of print.\u003c/li\u003e\n\u003cli\u003eKorth J, Wilde B, Dolff S, et al. SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients.\u003cem\u003e J Clin Virol.\u003c/em\u003e 2020;\u003cstrong\u003e128\u003c/strong\u003e:104437.\u003c/li\u003e\n\u003cli\u003eSharon H Bergquist,\u0026nbsp;Clyde Partin,\u0026nbsp;David L Roberts,\u0026nbsp;James B O'Keefe,\u0026nbsp;Elizabeth J Tong,\u0026nbsp;Jennifer Zreloff,\u0026nbsp;Thomas L Jarrett,\u0026nbsp;Miranda A Moore\u003cstrong\u003e.\u003c/strong\u003e Non-hospitalized Adults with COVID-19 Differ Noticeably from Hospitalized Adults in Their Demographic, Clinical, and Social Characteristics\u003cstrong\u003e. \u003c/strong\u003eSN Compr Clin Med.\u0026nbsp;2020 Aug 14;1-9.doi: 10.1007/s42399-020-00453-3.\u0026nbsp;Online ahead of print.\u003c/li\u003e\n\u003cli\u003eBaykan B, Ertas M, Karli N, et al. The burden of headache in neurology outpatient clinics in Turkey. \u003cem\u003ePain Pract.\u003c/em\u003e 2007;\u003cstrong\u003e7\u003c/strong\u003e:313-23.\u003c/li\u003e\n\u003cli\u003eBelvis R. Headaches During COVID-19: My Clinical Case and Review of the Literature. \u003cem\u003eHeadache.\u003c/em\u003e 2020;\u003cstrong\u003e60\u003c/strong\u003e:1422-1426.\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 1: Demographic features of participants and characteristics of headache experienced during the pandemic period\u003c/p\u003e\n\u003ctable border=\"1\" width=\"623\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003e(n=1968)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"190\"\u003e\n\u003cp\u003eCOVID-19 positive*\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"199\"\u003e\n\u003cp\u003eNo COVID-19#\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003ePrior headache (n=116)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003eNo prior headache (n=87)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ep\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003ePrior headache (n=138)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003eNo prior headache (n=383)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ep\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ep (1-3)\u0026dagger;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ep (2-4)\u0026Dagger;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eAge year,mean (SD)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e39.7 (11)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e38.2 (11)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.370\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e41.0 (10)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e42.2 (11)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.061\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.175\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.004\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eSex (male %)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e36.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e46.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.104\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e22.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e31.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.001\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.008\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eHealthcare worker (%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e44.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e43.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.541\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e46.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e48.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.239\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.366\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.255\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eHeadache duration hours mean (SD)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e52.1 (57)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e45.3 (53)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.430\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e38.4 (53)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e45.9 (63)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.039\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.014\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.949\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"7\" width=\"510\"\u003e\n\u003cp\u003eHeadache characteristics\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003ePulsating %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e50.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e32.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.008\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e55.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e42.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.202\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.064\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003ePressing %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e31.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e43.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.058\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e29.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e38.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.289\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.227\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eFiery %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e2.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e2.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.633\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e2.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e5.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.022\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.625\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.219\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eStabbing %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e12.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e16.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.330\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e11.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e11.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.497\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.315\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.142\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"7\" width=\"510\"\u003e\n\u003cp\u003eAccompanying symptoms\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eNausea %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e70.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e71.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.538\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e53.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e52.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.450\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.002\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003ePhonophobia %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e67.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e67.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.509\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e71.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e66.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.056\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.198\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.465\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003ePhotophobia %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e63.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e63.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.508\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e60.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e51.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.002\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.276\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.038\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eOsmophobia %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e39.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e50.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.090\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e30.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e28.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.292\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.044\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eAllodynia %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e31.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e41.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.024\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eAnosmia/ageusia %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e74.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e73.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.479\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e19.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e23.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.073\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eSore throat, rhinorrhea %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e62.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e70.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.152\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e41.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e54.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.006\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eStinging, burning, tearing in the eyes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e63.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e64.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.481\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e44.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e49.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.063\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.011\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eUse of analgesics %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e84.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e79.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.257\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e82.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e69.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.389\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.042\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eNo response to analgesics %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e16.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e22.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.227\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e7.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e8.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.353\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.002\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.002\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003ePartial response to analgesics \u003cu\u003e\u0026lt;\u003c/u\u003e50%) %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e38.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e38.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.530\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e25.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e37.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.006\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.484\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eImproved with analgesics \u0026gt;50%\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e32.0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e25.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.231\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e26.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e27.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.362\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.129\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.436\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"122\"\u003e\n\u003cp\u003eCompletely recovered with analgesics %\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"67\"\u003e\n\u003cp\u003e12.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"75\"\u003e\n\u003cp\u003e11.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.568\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e39.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"76\"\u003e\n\u003cp\u003e26.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"47\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"56\"\u003e\n\u003cp\u003e.000\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"57\"\u003e\n\u003cp\u003e.008\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003e*\u003c/strong\u003e Diagnosed by positive PCR test; \u003cstrong\u003e#\u003c/strong\u003e No COVID-19 symptoms or diagnosis; \u0026dagger;\u003cstrong\u003ep (1-3)\u003c/strong\u003e p value between the patients with prior headache with or without positive COVID-19 test; \u0026Dagger;\u003cstrong\u003ep (2-4)\u003c/strong\u003e p value between the patients with no prior headache with or without positive COVID-19 test (significant test values are marked as bold)\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2: Odds ratios of differentiating variables of the headache in patients with COVID-19 diagnosis \u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd width=\"151\"\u003e\n\u003cp\u003e\u003cstrong\u003eHeadache characteristics\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"102\"\u003e\n\u003cp\u003e\u003cstrong\u003eCOVID-19 positive\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003en (%)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"90\"\u003e\n\u003cp\u003e\u003cstrong\u003eNo COVID-19\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003en (%)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"54\"\u003e\n\u003cp\u003e\u003cstrong\u003eOR\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"151\"\u003e\n\u003cp\u003ePresence of anosmia/ageusia\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"102\"\u003e\n\u003cp\u003e142(74%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"90\"\u003e\n\u003cp\u003e282(%20)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"54\"\u003e\n\u003cp\u003e11.4\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"151\"\u003e\n\u003cp\u003eBilateral headache\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"102\"\u003e\n\u003cp\u003e166 (85%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"90\"\u003e\n\u003cp\u003e994 (64%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"54\"\u003e\n\u003cp\u003e3.37\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"151\"\u003e\n\u003cp\u003eAnalgesic-resistant\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"102\"\u003e\n\u003cp\u003e32(%18)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"90\"\u003e\n\u003cp\u003e116(8%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"54\"\u003e\n\u003cp\u003e2.61\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"151\"\u003e\n\u003cp\u003eGastrointestinal symptoms\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"102\"\u003e\n\u003cp\u003e137(70%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"90\"\u003e\n\u003cp\u003e808(53%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"54\"\u003e\n\u003cp\u003e2.13\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"151\"\u003e\n\u003cp\u003eMale gender\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"102\"\u003e\n\u003cp\u003e82(%40)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"90\"\u003e\n\u003cp\u003e437(25%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"54\"\u003e\n\u003cp\u003e2.06\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"151\"\u003e\n\u003cp\u003eHeadache duration \u0026gt;72 hours\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"102\"\u003e\n\u003cp\u003e27(13.3%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"90\"\u003e\n\u003cp\u003e130(7%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"54\"\u003e\n\u003cp\u003e1.93\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd width=\"151\"\u003e\n\u003cp\u003eHeadache duration \u0026gt; 48 hours\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"102\"\u003e\n\u003cp\u003e55(27%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"90\"\u003e\n\u003cp\u003e328(18.5%)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"54\"\u003e\n\u003cp\u003e1.63\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"the-journal-of-headache-and-pain","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"tjhp","sideBox":"Learn more about [The Journal of Headache and Pain](https://thejournalofheadacheandpain.biomedcentral.com/)","snPcode":"10194","submissionUrl":"https://submission.nature.com/new-submission/10194/3","title":"The Journal of Headache and Pain","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"COVID-19 infection, headache, migraine","lastPublishedDoi":"10.21203/rs.3.rs-59636/v2","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-59636/v2","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eBackground\u003c/p\u003e\u003cp\u003eHeadache is the most common COVID-19-related neurological symptom. We aimed to reveal diagnostic clues of headache for COVID-19 infection and to investigate the course of primary headaches during the pandemic.\u0026nbsp;\u003c/p\u003e\u003cp\u003eMethods\u003c/p\u003e\u003cp\u003eWe developed a detailed web-based questionnaire screening the characteristics and course of headaches besides clinical COVID-19 features. The participants were grouped according to being diagnosed with COVID-19 infection or not, and having previous or new-onset headaches. The COVID-19 related headache features and their associations with other clinical features were investigated. A binary logistic regression model was performed to differentiate the characteristics of headache related to COVID-19. \u003c/p\u003e\u003cp\u003eFindings \u003c/p\u003e\u003cp\u003eA total of 3458 participants (2341 females;67.7%, 1495 healthcare workers;43.2%) with a mean age of 43.21±11.2 years contributed to the survey. Among them, 262 participants had COVID-19 diagnosis and 126 (48.1%) were male. The rate of males in the group without COVID-19 was 31% (991 out of 3196 participants) showing significant gender difference between groups (p\u0026lt;0.000). COVID-19 related headaches were more closely associated with anosmia/ageusia and gastrointestinal complaints (p\u0026lt;0.000 and p\u0026lt;0.000), and showed different characteristics like pulsating, pressing, and even stabbing quality. Logistic regression analyses showed that bilateral headache, duration over 72 hours, analgesic resistance and having male gender were significant variables to differentiate COVID-19 positive patients from those without COVID-19 (p=0.04 for long duration and p\u0026lt;0.000 for others). A worsening of previous primary headaches due to the pandemic-related problems was not reported in the majority of patients.\u003c/p\u003e\u003cp\u003eInterpretation \u003c/p\u003e\u003cp\u003eBilateral, long-lasting headaches, resistance to analgesics and having male gender were more frequent in people with COVID-19 in conjunction with anosmia/ageusia and gastrointestinal complaints. These features may be helpful for diagnosing the headache related to COVID-19 during the pandemic.\u003c/p\u003e","manuscriptTitle":"Headache Characteristics In COVID-19 Pandemic-A Survey Study","msid":"","msnumber":"","nonDraftVersions":[{"code":2,"date":"2020-09-23 22:27:36","doi":"10.21203/rs.3.rs-59636/v2","editorialEvents":[{"type":"communityComments","content":0},{"type":"editorAssigned","content":"","date":"2020-09-18T12:00:00+00:00","index":"","fulltext":""},{"type":"decision","content":"Accept","date":"2020-09-18T12:00:00+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2020-09-17T12:00:00+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2020-09-17T12:00:00+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"the-journal-of-headache-and-pain","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"tjhp","sideBox":"Learn more about [The Journal of Headache and Pain](https://thejournalofheadacheandpain.biomedcentral.com/)","snPcode":"10194","submissionUrl":"https://submission.nature.com/new-submission/10194/3","title":"The Journal of Headache and Pain","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}},{"code":1,"date":"2020-08-19 21:51:49","doi":"10.21203/rs.3.rs-59636/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"editorInvitedReview","content":"","date":"2020-08-19T12:00:00+00:00","index":2,"fulltext":"Recommendation: Reviewer's comments unavailable due to the journal's policy.\n"},{"type":"decision","content":"Major revision","date":"2020-08-19T12:00:00+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2020-08-18T12:00:00+00:00","index":"","fulltext":""},{"type":"reviewersInvited","content":"","date":"2020-08-18T12:00:00+00:00","index":"","fulltext":""},{"type":"reviewerAgreed","content":"","date":"2020-08-18T12:00:00+00:00","index":1,"fulltext":""},{"type":"reviewerAgreed","content":"","date":"2020-08-18T12:00:00+00:00","index":2,"fulltext":""},{"type":"editorInvitedReview","content":"","date":"2020-08-18T12:00:00+00:00","index":1,"fulltext":"Recommendation: Reviewer's comments unavailable due to the journal's policy.\n"},{"type":"checksComplete","content":"","date":"2020-08-17T12:00:00+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2020-08-17T12:00:00+00:00","index":"","fulltext":""},{"type":"submitted","content":"","date":"2020-08-16T12:00:00+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"the-journal-of-headache-and-pain","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"tjhp","sideBox":"Learn more about [The Journal of Headache and Pain](https://thejournalofheadacheandpain.biomedcentral.com/)","snPcode":"10194","submissionUrl":"https://submission.nature.com/new-submission/10194/3","title":"The Journal of Headache and Pain","twitterHandle":"@BioMedCentral","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"BMC/SO AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"b4004925-eaf8-4c6d-8019-ffcfaee3f857","owner":[],"postedDate":"September 23rd, 2020","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":596240,"name":"Infectious Diseases"}],"tags":[],"updatedAt":"2020-10-18T15:02:15+00:00","versionOfRecord":{"articleIdentity":"rs-59636","link":"https://doi.org/10.1186/s10194-020-01188-1","journal":{"identity":"the-journal-of-headache-and-pain","isVorOnly":false,"title":"The Journal of Headache and Pain"},"publishedOn":"2020-10-13 12:00:00","publishedOnDateReadable":"October 13th, 2020"},"versionCreatedAt":"2020-09-23 22:27:36","video":"","vorDoi":"10.1186/s10194-020-01188-1","vorDoiUrl":"https://doi.org/10.1186/s10194-020-01188-1","workflowStages":[]},"version":"v2","identity":"rs-59636","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-59636","identity":"rs-59636","version":["v2"]},"buildId":"J0_U0BvcaRcwD8yVFaRlm","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}